Guardant Health Q4 revenue $126.9M (+17% YoY); net loss widens to $139.9M; guides FY23 rev $525-540M

Guardant Health, Inc.

2022-FY EPS reported -$6.41 revenue$449,538,000

Q4 revenue $126.9M (+17% YoY); full-year revenue $449.5M (+20% YoY).
Q4 clinical test volume 36,000 (+41% YoY); biopharma 8,200 (+24% YoY).
Q4 net loss $139.9M ($1.36/share) vs $90.9M ($0.89) prior year; non-GAAP net loss $119.6M.
FY23 revenue guidance $525-540M (17-20% growth); expects free cash outflow ~$350M.
ECLIPSE study for Shield CRC screening showed 83% sensitivity, 90% specificity; FDA approved Guardant360 CDx for breast cancer.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Guardant Health, Inc. reported the year ended December 31, 2022 results: revenue $449.5 million, net income $654.6 million, EPS $6.41 per share.

Period: the year ended December 31, 2022
Revenue: $449.5 million
Net income: $654.6 million
EPS: $6.41 per share
Result: reported results

Exact text from the filing

customers in the fourth quarter of 2022, representing an increase of 41% and 24%, respectively, over the fourth quarter of 2021. Full Year 2022 Financial Highlights • Revenue of $449.5 million for the full year 2022, an increase of 20% over the full year 2021. • Reported 124,800 tests to clinical customers and 26,000 tests to biopharmaceutical customers in the full

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Guardant Health, Inc. reported the three months ended December 31, 2022 results: revenue $126.9 million, net income $139.9 million, EPS $1.36 per share.

Period: the three months ended December 31, 2022
Revenue: $126.9 million
Net income: $139.9 million
EPS: $1.36 per share
Result: reported results

Exact text from the filing

data sets and advanced analytics, today reported financial results for the quarter and full year ended December 31, 2022. Fourth Quarter 2022 Financial Highlights • Revenue of $126.9 million for the fourth quarter of 2022, an increase of 17% over the fourth quarter of 2021. • Reported 36,000 tests to clinical customers and 8,200 tests to biopharmaceutical customers

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Guardant Health, Inc. filing history →

Source: SEC EDGAR

accession 0001576280-23-000019

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.